Geneos Therapeutics Raises $17M in Series A2 Funding


Geneos Therapeutics, a Plymouth Meeting, PA-based clinical stage biotherapeutics company, raised $17M in Series A2 funding.

The round was led by Flerie Invest with participation from Santé Ventures, Korea Investment Partners, Global Bio Fund, and INOVIO Pharmaceuticals. In conjunction with the financing, Dr. Ted Fjällman, Partner, Flerie Invest joined Geneos’ Board of Directors.

The company intends to use the funds to expand the GT-30 Phase Ib/IIa clinical trial, its pipeline into a new indication, and continued operations.

Geneos Therapeutics is a clinical stage biotherapeutics company focused on the development of tumor neoantigen targeted personalized immunotherapies. The proprietary GT-EPIC™ Neoantigen-Targeting Platform is based on the design and delivery of highly optimized synthetic DNA plasmids and their combinations for cancer immunotherapy. The platform allows Geneos to develop personalized therapies tailored to each patient’s unique tumor mutations.

The company’s GT-30 Phase Ib/IIa clinical trial evaluates Geneos’ personalized cancer vaccine, GNOS-PV02, for treating patients with advanced hepatocellular carcinoma (HCC), a type of liver cancer. GNOS-PV02, is a tumor-specific DNA plasmid-based product designed and manufactured for each patient based on their unique tumor mutations (neoantigens), identified by sequencing each patient’s tumor. 

In the trial, GNOS-PV02 is combined with a DNA encoded cytokine IL-12 (INO-9012) and PD-1 checkpoint inhibitor (pembrolizumab). Geneos will increase the number of patients treated from 24 to 36 patients.